Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Patients With Ulcerative Colitis
David T. Rubin 1, Britta Siegmund 2, Geert D’Haens 3, Peter Irving 4, Irina Blumenstein 5, Corey A. Siegel 6, Edward V. Loftus Jr 7, Douglas C. Wolf 8, Bincy Abraham 9, Freddy Caldera 10, Laurent Peyrin-Biroulet 11, Anjali Jain 12, Hsiuanlin Wu 12, Mark T. Osterman 12, Millie D. Long 13
1 University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA; 2 Charité – Universitätsmedizin Berlin, Berlin, Germany; 3 Amsterdam University Medical Center, Amsterdam, Netherlands; 4 Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 5 Goethe University Hospital, Frankfurt, Germany; 6 Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 7 Mayo Clinic College of Medicine and Science, Rochester, MN, USA; 8 Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, USA; 9 Houston Methodist-Weill Cornell, Houston, TX, USA; 10 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 11 Nancy University Hospital, Nancy, France; 12 Bristol Myers Squibb, Princeton, NJ, USA; 13 UNC Chapel Hill, Chapel Hill, NC, USA
;
